论文部分内容阅读
目的:探讨抗肿瘤药不良反应发生的特点,为临床安全用药提供参考。方法:收集某院2004～2008年的抗肿瘤药不良反应报告表661例,对抗肿瘤药不良反应所涉及的患者性别、年龄、药品、给药途径、临床表现、级别等项目进行定量分析。结果:661例报告表中,男430例(65.05%),女231例(34.95%),60岁以上的患者发生药品不良反应(ADR)191例(38.43%);涉及64种抗肿瘤药,涉及怀疑药物共计1 145例次;居前3位的药物是顺铂(210例次)、氟尿嘧啶(135例次)、奥沙利铂(124例次);静脉注射给药1 027例次(89.69%);涉及ADR临床症状共计1 566例次,消化系统损害773例次(49.36%)居首位;发生新的、严重的ADR共242例,占36.61%。结论:收集整理抗肿瘤药不良反应报告,定量分析、综合评价其基本信息,有助于促进抗肿瘤药临床合理应用,保障患者安全用药。
Objective: To investigate the characteristics of adverse reactions of antineoplastic agents and provide references for clinical safe medication. Methods: A total of 661 reports of antineoplastic adverse events were collected in a hospital from 2004 to 2008. The sex, age, drug, route of administration, clinical manifestation and level of the antineoplastic drugs were analyzed quantitatively. Results: Of the 661 reported cases, there were 430 males (65.05%) and 231 females (34.95%), and 191 (38.43%) ADRs were reported in patients over 60 years old. There were 64 anti-tumor drugs, A total of 1 145 cases of suspected drugs were involved. The top three drugs were cisplatin (210 cases), fluorouracil (135 cases) and oxaliplatin (124 cases) 89.69%). A total of 1 566 clinical symptoms were involved in ADR, with 773 episodes (49.36%) of digestive system ranking the first place. There were 242 cases (36.61%) of new and serious ADR. Conclusion: Collect and sort out the reports of adverse reactions of antineoplastic agents, quantitative analysis, and comprehensive evaluation of their basic information, which helps to promote the rational clinical application of antineoplastic agents and ensure the safety of patients.